(2015)
Interferon-gamma Immunotherapy in a Patient With Refractory Disseminated Candidiasis.
Pediatr Infect Dis J 34(12),
1391-1394.
Dr. Mark Gresnigt
Adaptive Pathogenicity Strategies · Head +49 3641 532-1305 mark.gresnigt@leibniz-hki.deCurriculum vitae
Main Research Areas
- Infection biology of human pathogenic fungi (Candida albicans)
- Immunology of fungal infections
- Host-pathogen interactions
- Fungal adaptation to the host
Professional Career
| Since 05/2020 |
Junior Research Group Leader, Leibniz Institute of Natural Product Research and Infection Biology - Hans Knoell Institute, Adaptive Pathogenicity Strategies |
| 05/2018- 05/2020 |
Alexander von Humboldt Foundation Postdoctoral Fellowship, Leibniz Institute of Natural Product Research and Infection Biology - Hans Knoell Institute, Dept. Microbial Pathogenicity Mechanisms |
| 03/2018-04/2018 | Language Course German, Dresden, Germany |
| 08/2015-03/2018 | Postdoctoral researcher, Radboud University Medical Center, Department of Internal medicine, Nijmegen Institute for Infectious Diseases. Project: The development of novel immunomodulatory strategies for disseminated fungal infections |
| 10/2010-05/2015 | Phd, Radboud University Nijmegen Medical Center, department of internal medicine, Nijmegen, The Netherlands. Project: Pattern recognition and cytokine signalling pathways in the host defence against Aspergillus fumigatus |
| 02/2008-08/2010 | M.Sc. Medical Biology, Radboud University, Nijmegen, The Netherlands |
| 07/2003-07/2007 | B.Sc. Biology and Medical Laboratory Research, Saxion University of Applied Sciences, Enschede, The Netherlands |
Awards · Appointments · Scientific Activities
| 2023 | Förderpreis, German Society for Hygiene and Microbiology (DGHM) |
| 2021 | Research award of the German speaking society for Mycology (DMykG) |
| 2021 | Science Award Life Sciences and Physics 2021 Beutenberg Campus e.V. Jena |
| Since 2021 | Member and PI of the DFG SFB/TR 124 programme "Pathogenic fungi and their human host: Networks of interaction – FungiNet'" |
| Since 2020 | DFG Emmy Noether grant |
| 2020 | Journal of Fungi Travel Award |
| 2020 | Co-Organizer of the FEBS advanced practical course “State-of-the-art infection models for human pathogenic fungi” in Jena, Germany |
| 2019 | PLoS Pathogens Postdoctoral Poster Award, Advanced lecture course on Human Fungal Pathogens |
| 2019 | ESCMID Research Grant 2019 |
| 2019 | Co-organizer of the winter school of the FunHoMic Marie Curie International Training Network |
| 2018-2021 | Two publication awards of the Deutschsprachigen Mykologischen Gesellschaft (DMykG; as co-author) |
| 2018 | Humboldt Research Fellowship for Postdoctoral Researchers |
| 2018 | Golden pipette award by the Laboratory for Experimental Internal Medicine Radboud University Nijmegen Medical center |
| 2016 | 3rd prize for best thesis by the Radboud institute for molecular life sciences (RIMLS) |
| 2015 | Van Beckum thesis Award for best PhD thesis in the field of immunology by the Dutch society for Immunology (NVVI) |
| 2015 | Youth development Prize by the German speaking society for Mycology (DMykG) |
| Since 2014 | Ad hoc reviewer for 19 journals eLife, PLoS Pathogens, mBio, Journal of Infectious Diseases, Frontiers Immunology, Cellular Microbiology, FEMS microbiology letters, Microbial Pathogenesis, Virulence, and others |
| 2013 | ALLFUN Investigators Award |
Publications
(2015)
An anti-inflammatory property of Candida albicans β-glucan: Induction of high levels of interleukin-1 receptor antagonist via a Dectin-1/CR3 independent mechanism.
Cytokine 71(2),
215-222.
(2015)
IL1B and DEFB1 Polymorphisms Increase Susceptibility to Invasive Mold Infection After Solid-Organ Transplantation.
J Infect Dis 211(10),
1646-1657.
(2014)
IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans.
Proc Natl Acad Sci U S A 111(9),
3526-3531.
(2014)
Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series.
BMC Infect Dis 14,
166.
(2014)
A polysaccharide virulence factor from Aspergillus fumigatus elicits anti-inflammatory effects through induction of Interleukin-1 receptor antagonist.
PLOS Pathog 10(3),
e1003936.
(2014)
The role of interleukin-1 family members in the host defence against Aspergillus fumigatus.
Mycopathologia 178(5-6),
395-401.
(2014)
Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37.
Front Microbiol 5,
762.
(2014)
The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus.
Diabetes Res Clin Pract 103(3),
395-401.
(2013)
Aspergillus fumigatus-induced IL-22 is not restricted to a specific Th cell subset and is dependent on complement receptor 3.
J Immunol 190(11),
5629-5639.
